“Research led by Mass General Hospital for Children suggests that almost 90% of rare disease experts are in favor of newborn genome sequencing for monogenic treatable disorders…’Early identification of infants who are at risk for genetic disorders can be lifesaving and screening has the potential to improve healthcare disparities for affected children,’ said lead author Nina Gold, a medical geneticist at Massachusetts General Hospital for Children, a member of Mass General Brigham, in a press statement.”
